Royalty Report: Drugs, Therapeutic, Diagnostic – Collection: 227291

$150.00

Curated Royalty Rate Report
Created On: 2020-07-15, Record Count: 8

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Created On: 2020-07-15
Record Count: 8

Primary Industries

  • Drugs
  • Therapeutic
  • Diagnostic
  • Disease
  • Diabetes Treatment
  • Wound Care
  • Cancer
  • Genome
  • obesity
  • Medical
  • Instruments
  • Surgical
  • Test/Monitoring
  • Drug Discovery

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 227291

License Grant
The University grants a license under the Patent Rights to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products in the Fields in the Territory and to develop and perform Licensed Processes in the Fields in the Territory.
License Property
The patents relate to Heparin Assay.

The heparin assay, anti–factor Xa assay, is designed to measure plasma heparin (UH and LMWH) levels and to monitor anticoagulant therapy. Heparin is a mixture of negatively charged glycosaminoglycans (sulfated mucopolysaccharides) that have anticoagulant properties due to their interaction with the natural anticoagulant antithrombin.

Field of Use
The Fields shall mean the Diagnostic Field. Research Reagent Field and Therapeutic Field, but shall specifically  exclude any use of the Heparinases in sequencing machines.

The Diagnostic Field shall mean clinical diagnostics using the Heparinases for in vitro testing of external tissue samples from patients.

Research Reagent Field shall mean research reagent uses of the Heparinases designated for research purposes only, not to be used in humans.

The Therapeutic Field shall mean human use of the Heparinases as therapeutics in pharmaceutical  compositions for reversal of anticoagulants, inflammation, reperfusion injury, restenosis and wound healing.

IPSCIO Record ID: 262411

License Grant
With this first amendment, the Parties add this new technology for Enzymes to the Patent.  The University grants for the Term, a worldwide license to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products and to develop and perform Licensed Processes, which the parties acknowledge, may result in the identification of Discovered Products, under Universitys rights in the Patent Rights Enzymes for Field Enzymes.
License Property
The patents are certain new intellectual property titled Delta 4.5 Glycuronidase, Matter and Composition, and Gene Sequence; 2-0 Sulfatase Gene – Gene Sequence and Expression;  and, Novel Mammalian Glycosaminoglycan Sulfatases.

The original agreement patent rights are for Heparin and Masspec for Field all but Machines;  for Case 9180 for Field Therapeutics;  for Case 9180 Background to enable and only to enable the practice of patent rights Case 9180; and patent rights Heparinase for Field Heparinase.

Field of Use
This amendment adds:
—  Field Enzymes meaning all fields of use, except for use of the enzymes described in the Patent Rights Enzymes as human therapeutics in pharmaceutical compositions and except for Field Sequencing Machines, and,
—  Field Research Reagents meaning the making, using and/or selling of enzymes and/or heparinases as reagents for research use by not-for-profit entities.

IPSCIO Record ID: 260415

License Grant
The University grants for the Term a worldwide license to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products and to develop and perform Licensed Processes, which the parties acknowledge may result in the identification of discovered products under Universitys rights.

University grants a first option to add Improvement to the Patent Rights, only in the fields for which exclusive rights, for six months after Company has been notified of the existence of each such Improvement.

License Property
The patent rights are for Heparin and Masspec for Field all but Machines;  for Case 9180 for Field Therapeutics;  for Case 9180 Background to enable and only to enable the practice of patent rights Case 9180; and patent rights Heparinase for Field Heparinase.

Patent titles include Solid-and Solution-Phase Synthesis of Heparin and Other Glycosaminoglycans;  
Synthesis of Oligosaccharides in Solution and on the Solid Support;  Linkers for Synthesis of Oligosaccharides on Solid-Support;  Protecting Groups Useful in the Synthesis of Polysaccharides, Natural Products, and Combinatorial Libraries;  Apparatus and Methods for the Automated Synthesis of Oligosaccharides;   Rationally Designed Heparinases Derived from Heparinase I and II;   System and Method for Notating Polymers;  and, Method for Identifying or Characterizing Properties of Polymeric Units.

Field of Use
The Field all but machines shall mean all fields of use except for the Field Sequencing Machines.

The Field Therapeutics shall mean for internal use in the discovery and development of therapeutic compounds;  and,  the clinical testing, manufacture and sale of therapeutic compounds.  This field shall not include the sale of research reagents or of synthesis machines.

The Field Heparinase shall mean all fields of use except for human use of heparinases as therapeutics in pharmaceutical compositions and except for Field Sequencing Machines.

IPSCIO Record ID: 209555

License Grant
This amendment adds Israel to the territory.  Pursuant to the original agreement, the Italian Licensor grants to the Israeli Company, an exclusive license in the Territory to practice under the Patent Rights and to utilize the Know-how in the Field of Use, and to register, make, have made, lease, use, market and/or sell Licensed Products and to practice Licensed Processes, until expiration or termination of the Patent Rights as hereinafter provided.

The Licensor hereby grants to the Company the right to grant sublicenses to third-parties.

License Property
The licensed property includes Heparin Derivatives and Process for Their Preparation; Salts of GAGs With Esters of Aminoacids, Preparations thereof and Pharmaceuticals Formulations Containing Them; and Pharmaceutical Compositions Containing Orally Absorbable Glycosaminoglycans.
Field of Use
The Field of Use shall mean the use of the Invention for the treatment of diabetic nephropathy, diabetic neuropathy and diabetic retinopathy.

IPSCIO Record ID: 248391

License Grant
University grants to Company an exclusive, worldwide license in the Patent Rights to make, have made, use, offer to sell, sell, have sold and imported Licensed Products in the Field, including research for development of Licensed Products.
License Property
University owns intellectual property rights which relate to therapeutic applications of RNAi, as described in Universitys invention entitled Methods and Synthesis of Reagents to Treat ALS.
Field of Use
The Field means Primary Field and Secondary Field collectively. Any commercial sale of research reagents covered by the Patent Rights is specifically excluded from the Field.

Primary Field means therapeutic, prophylactic, or diagnostic health care applications for amyotrophic lateral sclerosis (ALS), diabetes, and obesity, in humans.

Secondary Field means therapeutic, prophylactic, or diagnostic health care applications in humans that are not included in the Primary Field.

IPSCIO Record ID: 203255

License Grant
The University Licensor grants to the Licensee a nonexclusive license to make, have made on its behalf, use, offer to sell or sell, offer to lease or lease, import, or otherwise offer to dispose or dispose of Licensed Products in the Territory.
License Property
The Product is for a biomarker relating to warfarin sensitivity for use in a Warfarin Sensitivity Test.

Warfarin sensitivity testing (genotyping) may be used to help determine someone's likely sensitivity or, less commonly, resistance to warfarin and to help select appropriate doses. Warfarin is an anticoagulant, a drug that is prescribed to help prevent inappropriate blood clotting (thrombosis and thromboembolism) in people who are at risk, or to help keep an existing blood clotting condition from getting worse.

Field of Use
The use is for the Human clinical diagnostics field, including Research Use Only (RUO), lnvestigation Use Only, (IUO), Analyte Specific Reagents (ASR), and In Vitro Diagnostic (!VD) fields of use for anticoagulant dosing.

Licensee is a molecular diagnostics company focused on developing and commercializing our eSensor detection technology.

IPSCIO Record ID: 260416

License Grant
The University grants for the term a license under Universitys patent rights to develop, make, have made, use, sell, offer to sell, lease, and import Licensed Products in the Field Sequencing Machines in the Territory.

University grants to Licensee a first option to add improvements to the Patent Rights, only in the fields for which exclusive rights are granted.

License Property
The patents are for Heparinase, Masspec, and Sequencing.

Licensed Product shall mean any sequencing machine that, in whole or in part absent the license granted hereunder, when used would infringe one or more claims of the Patent Rights.

Heparanase, also known as HPSE, is an enzyme that acts both at the cell-surface and within the extracellular matrix to degrade polymeric heparan sulfate molecules into shorter chain length oligosaccharides.

Field of Use
The Field Sequencing Machines shall mean the commercial sale or leasing of sequencing machines, including the performance of sequencing services, but only to the extent such sequencing services are required for the seller or lessor of such a sequencing machine to develop or manufacture such sequencing machine; or performed by the purchaser of such a sequencing machine using the sequencing machine.

Licensee is also utilizing our ability to sequence, or analyze the molecular structure of, sugars, to create generic versions of complex sugar-based drugs, or technology-enabled generic products. Through detailed analysis of the molecular structure of complex sugars, our technology provides a more complete understanding of the roles that sugars play in cellular function, disease and drug action. Based on our understanding of complex sugars, Licensee has developed a diversified pipeline of novel discovery and development candidates and near-term product opportunities.

IPSCIO Record ID: 234445

License Grant
Licensee today announced that it has expanded its existing clinical collaboration agreement with Japanese Licensor to develop AndexXaâ„¢ (andexanet alfa) as an antidote for edoxaban, Licensor's Factor Xa inhibitor.

The parties agreed to amend the agreement to expedite the expansion of our Phase 4 trial of Andexxa.  The original agreement was entered into to study the safety and efficacy of Andexxa as a reversal agent to edoxaban, in our Phase 3 and Phase 4 studies.  The Licensee is responsible for the cost of conducting these clinical studies. Pursuant to our agreement with Licensor, Licensee is obligated to provide research, development and regulatory services and to manufacture and supply Andexxa.

License Property
Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo] is the first and only antidote for the Factor Xa inhibitors rivaroxaban and apixaban.

AndexXa (andexanet alfa), an investigational drug, is a modified human Factor Xa molecule that acts as a decoy to target and sequester with high specificity both oral and injectable Factor Xa inhibitors in the blood. Once bound, the Factor Xa inhibitors are unable to bind to and inhibit native Factor Xa, thus potentially allowing for the restoration of normal hemostatic processes. AndexXa is the first compound being studied as an antidote for Factor Xa inhibitors that directly and specifically reverses anti-Factor Xa activity – the anticoagulant mechanism of these agents.

Field of Use
This agreement pertains to the drug industry relating to therapeutics in the areas of thrombosis, other hematologic disorders and inflammation.

Licensee is developing andexanet alfa, a U.S. Food and Drug Administration (FDA)-designated Breakthrough Therapy, for patients treated with a direct or indirect Factor Xa inhibitor when reversal of anticoagulation is needed, such as for life-threatening or uncontrolled bleeding or emergency surgery and urgent procedures.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.